Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 250 Other hematologic neoplasm 199 Sarcoma 79 Plasma cell 74 CNS 72 Breast 71 Myeloid 63 Gynecologic 42 Genitourinary 42 Classical hematology 29 Dermatologic 25 Thoracic 15 Other solid neoplasm 14 Head & Neck 14 Gastrointestinal 14 Endocrine 4 Other neoplasm 2 Tumor-Agnostic 1

Conditions

Interventions

Paclitaxel 57 Gemcitabine 51 Carboplatin 51 Surveys and Questionnaires 48 Docetaxel 37 Bevacizumab 37 pembrolizumab 32 Nivolumab 29 Cisplatin 28 Fluorouracil 24 Capecitabine 23 Irinotecan 22 Erlotinib Hydrochloride 22 Sorafenib 20 Leucovorin 19 Afatinib 19 Radiotherapy 18 Pemetrexed 18 Oxaliplatin 17 Trastuzumab 16 Ipilimumab 15 regorafenib 14 Blood Specimen Collection 14 130-nm albumin-bound paclitaxel 14 olaparib 13 Interviews as Topic 13 Cetuximab 13 Albumin-Bound Paclitaxel 13 atezolizumab 12 Sunitinib 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Filgrastim × Tumor-Agnostic × Clear all

NCT01057264 2015-11-18

HAI Abraxane With Gemcitabine and Bevacizumab

M.D. Anderson Cancer Center

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡